H.C. Wainwright lifts Aurinia Pharmaceuticals Inc. [AUPH] price estimate. Who else is bullish?

Aurinia Pharmaceuticals Inc. [NASDAQ: AUPH] jumped around 0.57 points on Tuesday, while shares priced at $21.50 at the close of the session, up 2.72%. The company report on September 10, 2021 that Aurinia Pharmaceuticals to Participate in H.C. Wainwright 23rd Annual Global Investment Conference.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) announced that members of the senior management team will participate in the H.C. Wainwright & Co. 23rd Annual Global Investment Conference, September 13-15, 2021. The Aurinia presentation will be available on-demand beginning September 13, 2021 at 3 pm ET.

The audio webcast is available here. Interested parties can also register and access the presentation under “News/Events” through the “Investors” section of the Aurinia corporate website at www.auriniapharma.com. A replay of the webcast will be available on Aurinia’s website.

Aurinia Pharmaceuticals Inc. stock is now 55.46% up from its year-to-date (YTD) trading value. AUPH Stock saw the intraday high of $21.86 and lowest of $20.72 per share. The company’s 52-week high price is 21.73, which means current price is +121.19% above from all time high which was touched on 09/14/21.

Compared to the average trading volume of 3.82M shares, AUPH reached a trading volume of 5382607 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Aurinia Pharmaceuticals Inc. [AUPH]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AUPH shares is $11.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AUPH stock is a recommendation set at 1.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

H.C. Wainwright have made an estimate for Aurinia Pharmaceuticals Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on January 25, 2021. While these analysts kept the previous recommendation, H.C. Wainwright dropped their target price from $34 to $28. The new note on the price target was released on November 03, 2020, representing the official price target for Aurinia Pharmaceuticals Inc. stock. Previously, the target price had yet another raise to $20, while BTIG Research analysts kept a Buy rating on AUPH stock.

The Average True Range (ATR) for Aurinia Pharmaceuticals Inc. is set at 1.32, with the Price to Sales ratio for AUPH stock in the period of the last 12 months amounting to 46.54. The Price to Book ratio for the last quarter was 8.30, with the Price to Cash per share for the same quarter was set at 2.56.

How has AUPH stock performed recently?

Aurinia Pharmaceuticals Inc. [AUPH] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 18.46. With this latest performance, AUPH shares gained by 41.73% in over the last four-week period, additionally plugging by 55.46% over the last 6 months – not to mention a rise of 43.81% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AUPH stock in for the last two-week period is set at 77.10, with the RSI for the last a single of trading hit 83.01, and the three-weeks RSI is set at 72.84 for Aurinia Pharmaceuticals Inc. [AUPH]. The present Moving Average for the last 50 days of trading for this stock 14.48, while it was recorded at 20.23 for the last single week of trading, and 13.91 for the last 200 days.

Aurinia Pharmaceuticals Inc. [AUPH]: Deeper insight into the fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Aurinia Pharmaceuticals Inc. [AUPH] shares currently have an operating margin of -194.50. Aurinia Pharmaceuticals Inc.’s Net Margin is presently recorded at -204.88.

Return on Total Capital for AUPH is now -28.27, given the latest momentum, and Return on Invested Capital for the company is -29.81. Return on Equity for this stock declined to -30.14, with Return on Assets sitting at -25.98. When it comes to the capital structure of this company, Aurinia Pharmaceuticals Inc. [AUPH] has a Total Debt to Total Equity ratio set at 2.06. Additionally, AUPH Total Debt to Total Capital is recorded at 2.02, with Total Debt to Total Assets ending up at 1.81. Long-Term Debt to Equity for the company is recorded at 1.87, with the Long-Term Debt to Total Capital now at 1.83.

Reflecting on the efficiency of the workforce at the company, Aurinia Pharmaceuticals Inc. [AUPH] managed to generate an average of -$349,252 per employee. Receivables Turnover for the company is 72.32 with a Total Asset Turnover recorded at a value of 0.13.Aurinia Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 11.30 and a Current Ratio set at 11.90.

Insider trade positions for Aurinia Pharmaceuticals Inc. [AUPH]

There are presently around $1,055 million, or 45.10% of AUPH stock, in the hands of institutional investors. The top three institutional holders of AUPH stocks are: FMR LLC with ownership of 8,523,007, which is approximately -8.458% of the company’s market cap and around 0.40% of the total institutional ownership; ORBIMED ADVISORS LLC, holding 6,069,032 shares of the stock with an approximate value of $130.48 million in AUPH stocks shares; and NEA MANAGEMENT COMPANY, LLC, currently with $111.21 million in AUPH stock with ownership of nearly 0% of the company’s market capitalization.

>> 7 Top Picks for the Post-Pandemic Economy <<

Positions in Aurinia Pharmaceuticals Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 88 institutional holders increased their position in Aurinia Pharmaceuticals Inc. [NASDAQ:AUPH] by around 7,739,335 shares. Additionally, 72 investors decreased positions by around 10,841,918 shares, while 32 investors held positions by with 30,472,195 shares. The mentioned changes placed institutional holdings at 49,053,448 shares, according to the latest SEC report filing. AUPH stock had 30 new institutional investments in for a total of 1,199,972 shares, while 32 institutional investors sold positions of 5,173,419 shares during the same period.

Share on facebook
Share on twitter
Share on linkedin
Share on skype
Share on reddit

Leave a Comment

Your email address will not be published. Required fields are marked *



Download Free eBook For


100% free. stop anytime no spam



Download Free eBook For


100% free. stop anytime no spam